Here, we have identified inactivation of JNK signalling, specifically loss of the JNK kinase MAP2K7, as a major determinant of insensitivity to combined endocrine therapy and CDK4/6 inhibition in ER+ breast cancer. Here, MAP2K7 is linked to breast cancer.